Technology Networks
Lab21 Launches new Commercial Companion Diagnostic Service for HIV Tropism in UK
Company becomes the first commercial reference laboratory in the UK to provide a companion diagnostic service for the HIV drug, Celsentri.
NEC and SomaLogic Enter Agreement to Prepare for Delivery of Novel Forms of Health Information via Cloud Services
Partnership seeks to accelerate worldwide clinical use of SomaLogic’s aptamer-based diagnostic technology.
New Life Science Conference: “Molecular Diagnostics Europe” at BIOTECHNICA 2010
Focus on new testing systems for the rapid diagnosis of cancer and infectious diseases.
Sanger Institute and Horizon Collaboration to Advance the Frontiers of Translational Genomics
The collaboration aims to translate the abundance of new information on human genetic variation into more effective treatments for cancer.
BioFortis and CHI Announce Biorepository Information Technology Strategic Partnership
Partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.
Inflammatory Markers in Leg Ulcer Fluid from Chronic Venous Insufficiency
Victor Babes National Institute and Colentina Clinical Hospital

The purpose of our study was to evaluate soluble matrixmetalloproteinases (MMPs) and their inhibitor (TIMP1) associated to leg ulcer wound fluid in comparison with the tissue localized ones. We aimed to develop an easy-to-perform protocol for the quantification of soluble MMPs / TIMP and associate the obtained levels with the disease stage and prognostic.
Development of Biomarkers for Improved Diagnosis of Active Tuberculosis
Proteome Systems Ltd

Proteome Systems has identified TB proteins in sputa and blood of people diagnosed with TB. Several of these proteins have been prioritised for ongoing validation. This involves generation of sensitive antibodies and optimisation of assays for detection of TB antigens in clinical samples. This presentation will discuss our progress in this program and our strategy for incorporation of these markers into a diagnostic test format.
Determination of the Autoantibody Repertoire in Autoimmune Diseases with Factor Protein Arrays – A new Approach to Personalized Therapies
Protagen AG,

Recently, we have presented a strategy to identify new marker molecules characteristic for Alopecia areata by combining protein microarray technology with the use of large cDNA expression libraries (Lueking et al., 2005). This strategy is now applied to Juvenile idiopathic Arthritis (JIA), Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS) in a BMBF-funded project.
Protein NMR/Biophysics Research Associate (BS/MS)
Novartis Institutes for BioMedical Research
We are committed to discovering innovative medicines to cure disease and improve human health. By hiring the best academic, biotech, and pharmaceutical trained scientists, we have fostered an atmosphere for drug discovery where innovation is rewarded.
Senior Account Manager/Account Director
Alto Marketing
The best career move for a well-connected marketing professional with real leadership ability and drive!
Senior Scientific Marketing Writer - Life Sciences
Alto Marketing
For a challenging career using your advanced life science background and writing strengths, please read on.
Post-doctoral position at INRA (France)
INRA
An 18-month post-doctoral position is available at INRA Clermont-Ferrand-Theix (France).The position is opened to both French and foreign applicants.
Engineer Technician, Fayetteville, Arizona, USA
SFC-Fluidics
SFC Fluidics is looking to hire a highly motivated, detail-oriented engineer technician.

oral communication skills . Experience with GMP and GLP desired
Computational Medicinal Chemistry Post-Doc Position, Siena, Italy
University of Siena
NatSynDrugs Is Seeking Candidates For a Computational Medicinal Chemistry Post-Doc Position
Automation Engineer, Metabolism, Agios Pharmaceuticals, Cambridge, MA, USA
Agios Pharmaceuticals
With new research showing that cancer cells become addicted to using more nutrients than normal cells to promote their rapid growth, there is an unprecedented opportunity to create a new class of oncology therapeutics that target a fundamental and ubiquitous mechanism in cancer cells. The intersection of these two fields of research - cancer and metabolism- represents an important and novel approach to treating cancer.
Senior Scientist, Metabolism
Agios
Agios Pharmaceuticals is seeking a PhD Scientist to join a team that is building and applying a state-of-art approach to investigate the intersection of cancer cell biology and metabolism.
The EMBO Meeting 2010 - Advancing the life sciences
04 September 2010 - 07 September 2010

Barcelona, Spain
Submit late abstracts by 30 July & register until 15 August

Programme includes: presentations by 120 world-class researchers, e.g. Elizabeth Blackburn and Cliff Tabin, 21 workshops spanning the life sciences, stand-alone poster sessions, on-site childcare and plenty of opportunities to meet fellow scientists.
Cyprotex 6th North American Drug Discovery Workshop
23 September 2010 - 23 September 2010

Following the success of our previous workshops, we are pleased to announce our 6th North American event which features a number of outstanding speakers in the ADMET/DMPK field to present on a range of relevant topics and specific approaches to ADMET within the industry.
Personalised Medicine
11 October 2010 - 12 October 2010

Attend SMi’s 2010 Personalised Medicine conference to study the latest developments in the science and the latest business strategies and partnership models moving the industry nearer to a personalised future.
To get more information on this conference please visit www.smi-online.co.ukl/personalised11.asp
  
Lessons Learned From HTS: The Short and Long Journey to Probe Discovery

Hakim Djaballah, Director, Memorial Sloan Kettering Cancer Center, speaking at Probe Discovery 2009
Lead-discovery and Probe Development in Smaller Academic-based HTS Labs

Andy Mesecar, Professor, University of Illinois, speaking at Probe Discovery 2009
Exploratory Pharmacogenetic Analysis of Efalizumab Responders

Emmanuel Monnet, Head of Biomarker, Merck Serono, speaking at Molecular Diagnostics World Congress 2009
The Future of Molecular Diagnostics: Innovative technologies driving market opportunities in personalized medicine
Business Insights

This report analyzes the current and potential world markets for molecular diagnostics, including advances in the field. This report generally forecasts future growth to 2015. The report breaks down market forecasts by type of test and by geography. It indicates which companies have key products in the market place. It also analyzes key drivers of this market.
Impact of Pharmacogenomics on Public Healthcare Policy: Educating patients, payors and healthcare providers
Business Insights

Impact of Pharmacogenomics on Public Healthcare Policy: Educating patients, payors and regulators is a report that examines how PGx implementations can help to improve efficiency and productivity within the industry, across the fields of pharma, biotech and diagnostics. The PGx strategies of major companies are profiled and recent alliances and licensing opportunities are highlighted.